Imashuku S, Hibi S, Kataoka-Morimoto Y, Yoshihara T, Ikushima S, Morioka Y, Todo S
Division of Paediatrics, Children's Research Hospital, Kyoto Prefectural University of Medicine, Japan.
Br J Haematol. 1995 Jan;89(1):188-90. doi: 10.1111/j.1365-2141.1995.tb08928.x.
Myelodysplasia and acute myeloid leukaemia (MDS/AML) developed in three cases of severe aplastic anaemia (SAA) and one case of congenital neutropenia (CN, Kostmann's disease) who received recombinant human granulocyte colony-stimulating factor (G-CSF) are reported. In these four MDS/AML cases, age at diagnosis of SAA/CN was 0-13 years, the cumulative dose of G-CSF was 98 micrograms/kg to 10 mg/kg over 1-57 months, and the interval from initiation of G-CSF to MDS/AML was 25, 23, 31 and 57 months, respectively. These results suggest a link between SAA/CN and MDS/AML in relation to G-CSF administration; however, large studies are necessary to determine if such a risk is significant in patients with SAA/CN who are treated with G-CSF.
据报告，3例严重再生障碍性贫血（SAA）患者和1例先天性中性粒细胞减少症（CN， Kostmann病）患者在接受重组人粒细胞集落刺激因子（G-CSF）治疗后发生了骨髓增生异常综合征和急性髓系白血病（MDS/AML）。在这4例MDS/AML病例中，SAA/CN诊断时的年龄为0至13岁，G-CSF的累积剂量在1至57个月内为98微克/千克至10毫克/千克，从开始使用G-CSF到发生MDS/AML的间隔时间分别为25、23、31和57个月。这些结果提示，在使用G-CSF方面，SAA/CN与MDS/AML之间存在联系；然而，需要开展大型研究来确定这种风险在接受G-CSF治疗的SAA/CN患者中是否显著。
